1. Home
  2. RVMDW vs CENX Comparison

RVMDW vs CENX Comparison

Compare RVMDW & CENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • CENX
  • Stock Information
  • Founded
  • RVMDW 2014
  • CENX 1995
  • Country
  • RVMDW United States
  • CENX United States
  • Employees
  • RVMDW 534
  • CENX N/A
  • Industry
  • RVMDW
  • CENX Aluminum
  • Sector
  • RVMDW
  • CENX Industrials
  • Exchange
  • RVMDW Nasdaq
  • CENX Nasdaq
  • Market Cap
  • RVMDW N/A
  • CENX N/A
  • IPO Year
  • RVMDW N/A
  • CENX 1996
  • Fundamental
  • Price
  • RVMDW $0.10
  • CENX $19.40
  • Analyst Decision
  • RVMDW
  • CENX Strong Buy
  • Analyst Count
  • RVMDW 0
  • CENX 3
  • Target Price
  • RVMDW N/A
  • CENX $23.00
  • AVG Volume (30 Days)
  • RVMDW 15.6K
  • CENX 2.3M
  • Earning Date
  • RVMDW 02-26-2025
  • CENX 04-30-2025
  • Dividend Yield
  • RVMDW N/A
  • CENX N/A
  • EPS Growth
  • RVMDW N/A
  • CENX N/A
  • EPS
  • RVMDW N/A
  • CENX 3.27
  • Revenue
  • RVMDW $742,000.00
  • CENX $2,220,300,000.00
  • Revenue This Year
  • RVMDW N/A
  • CENX $11.16
  • Revenue Next Year
  • RVMDW N/A
  • CENX $3.93
  • P/E Ratio
  • RVMDW N/A
  • CENX $5.93
  • Revenue Growth
  • RVMDW N/A
  • CENX 1.60
  • 52 Week Low
  • RVMDW $0.10
  • CENX $11.35
  • 52 Week High
  • RVMDW $0.12
  • CENX $25.39
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • CENX 51.78
  • Support Level
  • RVMDW N/A
  • CENX $16.45
  • Resistance Level
  • RVMDW N/A
  • CENX $19.35
  • Average True Range (ATR)
  • RVMDW 0.00
  • CENX 1.44
  • MACD
  • RVMDW 0.00
  • CENX 0.00
  • Stochastic Oscillator
  • RVMDW 0.00
  • CENX 68.45

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: